Showing results (111-120 of 282) with videos related to
Sort By:
Pageof 29
The Lancet. Oncology|February 3, 2020
CAR T-cell product performance in haematological malignancies before and after marketing authorisationMagdi Elsallab, Bruce L Levine, Alan S Wayne, et al.Blood|December 16, 2006
Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemiaOlga Sala-Torra, Holly M Gundacker, Derek L Stirewalt, et al.Blood|September 26, 2009
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsMartin C Müller, Jorge E Cortes, Dong-Wook Kim, et al.American Journal of Hematology|October 23, 2019
Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemiaElizabeth F Krakow, Boglarka Gyurkocza, Barry E Storer, et al.Archives of Pediatrics & Adolescent Medicine|August 9, 2006
Psychotropic medication use in pediatric patients with cancerMaryland Pao, Elizabeth D Ballard, Donald L Rosenstein, et al.Blood|October 26, 2006
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemiaVivian G Oehler, Ted Gooley, David S Snyder, et al.BMC Cancer|April 4, 2013
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemiaAndrew M Stein, Giovanni Martinelli, Timothy P Hughes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinibSusan Branford, Dong-Wook Kim, Simona Soverini, et al.Leukemia & Lymphoma|October 23, 2002
Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantationUwe Platzbecker, Ted Gooley, Claudio Anasetti, et al.International Journal of Hematology|March 25, 2014
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) studyMichele Baccarani, Brian J Druker, Susan Branford, et al.Pageof 29